2025-10-24 - Analysis Report
Okay, here's an analysis of TransMedics Group Inc. (TMDX) based on the data you provided.

## TMDX (TransMedics Group Inc.) Analysis

**Company Overview:** TransMedics Group Inc. is a medical technology company focused on developing and delivering innovative organ preservation and assessment solutions for transplantation.

### 1. Performance Relative to S&P 500 (VOO)

*   **TMDX Cumulative Return:** 200.89%
*   **VOO Cumulative Return:** 74.33%
*   **Absolute Divergence:** 122.3
*   **Relative Divergence:** 61.2 (Indicates TMDX's outperformance is in the 61.2th percentile of its historical divergence range compared to VOO).

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO). The relative divergence suggests that while the outperformance is substantial, it's positioned in the upper half of its historical range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2019-2021  | -18.0% | 83.5%  | -61.0% | -0.0 | 0.7    |
| 2020-2022  | 94.0%  | 83.5%  | 95.0%  | 0.0  | 2.3    |
| 2021-2023  | 65.0%  | 80.5%  | 64.0%  | 0.1  | 2.9    |
| 2022-2024  | 130.0% | 85.5%  | 109.0% | 0.1  | 2.3    |
| 2023-2025  | 122.0% | 85.5%  | 58.0%  | 0.3  | 4.4    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate varies significantly across different periods, showing high growth potential in recent years (2020-2025).
*   **MDD:** The Maximum Drawdown is very high, indicating significant volatility and risk.
*   **Alpha:** Positive Alpha values indicate TMDX's ability to generate excess returns compared to its benchmark, particularly strong from 2020 onwards.
*   **Beta:** Low Beta values suggest the stock is not highly correlated with the market, offering potential diversification benefits.

### 2. Recent Price Action

*   **Current Price:** 120.13
*   **Last Market Data:** Price: 128.91, Previous Close: 119.54, Change: 7.84
*   **5-day Moving Average:** 117.19
*   **20-day Moving Average:** 114.42
*   **60-day Moving Average:** 116.59

**Analysis:** The recent price jump (Change: 7.84) signifies a potentially bullish move. The price is above all three moving averages, further supporting a positive short-term trend.

### 3. Technical Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 58.18 (Neutral, neither overbought nor oversold)
*   **PPO:** 0.75 (Positive, indicating a potential uptrend)
*   **Hybrid Signal:** Buy 100% (Very Safe)
*   **Recent (20-day) Relative Divergence Change:** 7.1 (+) (Short-term increase in outperformance)
*   **Expected Return:** 49.6% (Long-term, relative to S&P 500)

**Analysis:** The MRI suggests a favorable investment environment, and the Hybrid Signal reinforces a buy recommendation. The positive PPO and increasing relative divergence support a bullish outlook. The substantial expected return indicates significant long-term growth potential relative to the S&P 500. The large change in price for the last market data should be considered when looking at the other indexes.

### 4. Recent News & Significant Events

*   **Positive Analyst Upgrades:** Needham upgraded TMDX to Buy with a $148 price target. Jefferies initiated coverage with a Buy rating and a $145 price target.
*   **Strong Relative Strength:** TMDX earned a Relative Strength Rating Upgrade from Investor's Business Daily.
*   **Upcoming Earnings Report:** TMDX is scheduled to report Q3 2025 financial results on October 29, 2025.

**Analysis:** Recent news is overwhelmingly positive, driven by analyst upgrades and recognition of strong relative strength. Investors will be watching the Q3 earnings report closely.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.75)
*   **Target Price:** Average: $141.64, High: $170.00, Low: $114.00

**Analysis:** The analyst consensus is strongly bullish, with an average price target significantly above the current price. This suggests considerable upside potential.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-07-30 | 0.92 | 0.48         |
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |

**Analysis:** TMDX has consistently beaten EPS expectations in recent quarters, indicating strong financial performance and effective management.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.16B    | 61.38%        |
| 2025-03-31 | $0.14B    | 61.47%        |
| 2024-12-31 | $0.12B    | 59.21%        |
| 2024-09-30 | $0.11B    | 55.94%        |
| 2024-06-30 | $0.11B    | 60.59%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE     |
|------------|-----------|---------|
| 2025-06-30 | $0.32B    | 10.97%  |
| 2025-03-31 | $0.27B    | 9.64%   |
| 2024-12-31 | $0.23B    | 3.00%   |
| 2024-09-30 | $0.21B    | 2.01%   |
| 2024-06-30 | $0.19B    | 6.42%   |

**Analysis:** Revenue is consistently growing, and profit margins are very high.  ROE has significantly increased, indicating improved profitability and efficient use of equity.

### 7. Overall Assessment

TransMedics Group (TMDX) presents a compelling investment case based on the provided data. The company has significantly outperformed the S&P 500, driven by strong revenue growth, high profit margins, and consistent earnings beats. Analyst sentiment is overwhelmingly positive, with numerous recent upgrades and high price targets.  Technical indicators also support a bullish outlook.

**Key Positives:**

*   Strong revenue growth and high profit margins.
*   Consistent earnings beats.
*   Positive analyst sentiment and upgrades.
*   Bullish technical indicators (MRI, PPO, Hybrid Signal).
*   High expected return relative to S&P 500.

**Key Considerations:**

*   High Maximum Drawdown indicates significant volatility.
*   The stock price has increased a lot with the recent news

**Conclusion:**

Based on this analysis, TMDX appears to be a promising investment opportunity, especially for investors with a long-term horizon. The recent positive news, coupled with strong financial performance and bullish technical indicators, suggests continued growth potential. However, investors should be aware of the high volatility associated with the stock and conduct further due diligence before making any investment decisions.
